102 related articles for article (PubMed ID: 6256019)
1. Enzyme therapy XVII: metabolic and immunologic evaluation of alpha- galactosidase A replacement in Fabry disease.
Desnick RJ; Dean KJ; Grabowski GA; Bishop DF; Sweeley CC
Birth Defects Orig Artic Ser; 1980; 16(1):393-413. PubMed ID: 6256019
[TBL] [Abstract][Full Text] [Related]
2. Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes.
Desnick RJ; Dean KJ; Grabowski G; Bishop DF; Sweeley CC
Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5326-30. PubMed ID: 228284
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease.
Ishii S; Chang HH; Yoshioka H; Shimada T; Mannen K; Higuchi Y; Taguchi A; Fan JQ
J Pharmacol Exp Ther; 2009 Mar; 328(3):723-31. PubMed ID: 19106170
[TBL] [Abstract][Full Text] [Related]
4. [Substrate specificity of multiple forms of human alpha-D-galactosidase and alpha-D-fucosidase].
Baskaeva EM; Shono NI; Kozlova IK; Vidershaĭn GIa
Biokhimiia; 1989 Mar; 54(3):421-6. PubMed ID: 2546612
[TBL] [Abstract][Full Text] [Related]
5. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
6. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.
Ioannou YA; Zeidner KM; Gordon RE; Desnick RJ
Am J Hum Genet; 2001 Jan; 68(1):14-25. PubMed ID: 11115376
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
[TBL] [Abstract][Full Text] [Related]
10. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
Barbey F; Widmer U; Burnier M; Lidove O
Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
[TBL] [Abstract][Full Text] [Related]
11. Kidney transplantation and enzyme alpha-galactosidase A therapy in patient with Fabry disease: a case report.
Dziemianko I; Jezior D; Boratyńska M; Patrzałek D; Kuźniar J; Szyber P; Klinger M
Transplant Proc; 2007 Nov; 39(9):2925-7. PubMed ID: 18022018
[TBL] [Abstract][Full Text] [Related]
12. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease.
Kizhner T; Azulay Y; Hainrichson M; Tekoah Y; Arvatz G; Shulman A; Ruderfer I; Aviezer D; Shaaltiel Y
Mol Genet Metab; 2015 Feb; 114(2):259-67. PubMed ID: 25155442
[TBL] [Abstract][Full Text] [Related]
14. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.
Schiffmann R; Murray GJ; Treco D; Daniel P; Sellos-Moura M; Myers M; Quirk JM; Zirzow GC; Borowski M; Loveday K; Anderson T; Gillespie F; Oliver KL; Jeffries NO; Doo E; Liang TJ; Kreps C; Gunter K; Frei K; Crutchfield K; Selden RF; Brady RO
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):365-70. PubMed ID: 10618424
[TBL] [Abstract][Full Text] [Related]
15. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
16. Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease.
Boscaro F; Pieraccini G; la Marca G; Bartolucci G; Luceri C; Luceri F; Moneti G
Rapid Commun Mass Spectrom; 2002; 16(16):1507-14. PubMed ID: 12203240
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of human alpha-galactosidase isozymes: comparison of tissue and plasma forms and evaluation of purification methods.
Bishop DF; Dean KJ; Sweeley CC; Desnick RJ
Birth Defects Orig Artic Ser; 1980; 16(1):17-32. PubMed ID: 6256017
[No Abstract] [Full Text] [Related]
18. Enzyme replacement therapy in Gaucher's and Fabry's disease.
Pentchev PG
Ann Clin Lab Sci; 1977; 7(3):251-3. PubMed ID: 404951
[TBL] [Abstract][Full Text] [Related]
19. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.
Mills K; Vellodi A; Morris P; Cooper D; Morris M; Young E; Winchester B
Eur J Pediatr; 2004 Oct; 163(10):595-603. PubMed ID: 15243806
[TBL] [Abstract][Full Text] [Related]
20. Enzyme therapy: II. Effect of covalent attachment of polyethylene glycol on biochemical parameters and immunological determinants of beta-glucosidase and alpha-galactosidase.
Wieder KJ; Davis FF
J Appl Biochem; 1983; 5(4-5):337-47. PubMed ID: 6207160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
